PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
AnemiaCoronary DiseaseCoronary Artery DiseaseCoronary StenosisCoronary OcclusionSystemic Inflammatory ResponseBleedingEpigenetic Disorder
Interventions
DRUG

Erythropoietin

"* Treatment regimen for hospitalized patients awaiting non-urgent surgeries: Administer EPO 600 IU/kg/week via subcutaneous (SC) or intravenous (IV) route, followed by 300 IU/kg/day via SC or IV 10 days before surgery. If ferritin \< 100 ng/dL, supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 1000 mg/week).~* Treatment regimen for hospitalized patients awaiting non-urgent surgeries with less than 5 days until surgery: Administer 40000 UI of EPO intravenous (IV) attack and supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 2000 mg/week), then 300UI/Kg/day IV or SC of EPO until day of surgery."

PROCEDURE

blood transfusion

"After surgery, this group will receive one unit of RBC at the moment of ICU admission.~Hb \> 8 g/dl: 1 unit of RBC. HB \< 8 g/dl: 2 units of RBC."

Trial Locations (1)

04024-002

RECRUITING

Leonardo Ohashi, São Paulo

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

Federal University of São Paulo

OTHER